Nektar Therapeutics (NKTR) stock
NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$35.91−0.53 (-1.45%)
Close on Nov 17, 2026Market cap $1.23BP/E –Yield –
Nektar Therapeutics cash
Cash and short-term investments held at the end of each period.
Nektar Therapeutics's cash was $684.34M at Jun 30, 2026. For fiscal 2025 it was $245.75M, down 3.7% from the year before. Over ten years it grew 16.0% a year on average. The highest annual figure on record is $1.34B in fiscal 2018.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $245.75M | -3.7% |
| FY2024 | Dec 31, 2024 | $255.23M | -15.9% |
| FY2023 | Dec 31, 2023 | $303.62M | -39.9% |
| FY2022 | Dec 31, 2022 | $504.98M | -31.2% |
| FY2021 | Dec 31, 2021 | $733.96M | -30.9% |
| FY2020 | Dec 31, 2020 | $1.06B | -19.8% |
| FY2019 | Dec 31, 2019 | $1.32B | -0.8% |
| FY2018 | Dec 31, 2018 | $1.34B | +350.9% |
| FY2017 | Dec 31, 2017 | $296.13M | +396.5% |
| FY2016 | Dec 31, 2016 | $59.64M | +7.3% |
| FY2015 | Dec 31, 2015 | $55.57M | +349.4% |
| FY2014 | Dec 31, 2014 | $12.37M | -68.3% |
| FY2013 | Dec 31, 2013 | $39.07M | +53.6% |
| FY2012 | Dec 31, 2012 | $25.44M | -93.9% |
| FY2011 | Dec 31, 2011 | $414.90M | +2236.8% |
| FY2010 | Dec 31, 2010 | $17.76M | -64.2% |
| FY2009 | Dec 31, 2009 | $49.60M | -68.1% |
| FY2008 | Dec 31, 2008 | $155.58M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $684.34M | +213.0% |
| Q4 FY2025 | Dec 31, 2025 | $245.75M | -3.7% |
| Q3 FY2025 | Sep 30, 2025 | $270.21M | +10.5% |
| Q2 FY2025 | Jun 30, 2025 | $175.90M | -35.1% |
| Q1 FY2025 | Mar 31, 2025 | $218.63M | -24.4% |
| Q4 FY2024 | Dec 31, 2024 | $255.23M | -15.9% |
| Q3 FY2024 | Sep 30, 2024 | $244.50M | -34.4% |
| Q2 FY2024 | Jun 30, 2024 | $271.24M | -33.8% |
| Q1 FY2024 | Mar 31, 2024 | $289.24M | -36.7% |
| Q4 FY2023 | Dec 31, 2023 | $303.62M | -39.9% |
| Q3 FY2023 | Sep 30, 2023 | $372.66M | -31.8% |
| Q2 FY2023 | Jun 30, 2023 | $409.43M | -33.9% |
| Q1 FY2023 | Mar 31, 2023 | $456.83M | -31.5% |
| Q4 FY2022 | Dec 31, 2022 | $504.98M | -31.2% |
| Q3 FY2022 | Sep 30, 2022 | $546.39M | -40.7% |
| Q2 FY2022 | Jun 30, 2022 | $619.32M | -38.1% |
| Q1 FY2022 | Mar 31, 2022 | $667.03M | -35.7% |
| Q4 FY2021 | Dec 31, 2021 | $733.96M | -30.9% |
| Q3 FY2021 | Sep 30, 2021 | $921.08M | -3.7% |
| Q2 FY2021 | Jun 30, 2021 | $1.00B | -3.7% |
| Q1 FY2021 | Mar 31, 2021 | $1.04B | -22.9% |
| Q4 FY2020 | Dec 31, 2020 | $1.06B | -19.8% |
| Q3 FY2020 | Sep 30, 2020 | $956.01M | -36.1% |
| Q2 FY2020 | Jun 30, 2020 | $1.04B | -31.5% |
| Q1 FY2020 | Mar 31, 2020 | $1.35B | -3.1% |
| Q4 FY2019 | Dec 31, 2019 | $1.32B | -0.8% |
| Q3 FY2019 | Sep 30, 2019 | $1.50B | +5.3% |
| Q2 FY2019 | Jun 30, 2019 | $1.52B | +66.3% |
| Q1 FY2019 | Mar 31, 2019 | $1.39B | +3889.8% |
| Q4 FY2018 | Dec 31, 2018 | $1.34B | +350.9% |
| Q3 FY2018 | Sep 30, 2018 | $1.42B | +3641.2% |
| Q2 FY2018 | Jun 30, 2018 | $911.13M | +5542.0% |
| Q1 FY2018 | Mar 31, 2018 | $34.81M | +48.2% |
| Q4 FY2017 | Dec 31, 2017 | $296.13M | +396.5% |
| Q3 FY2017 | Sep 30, 2017 | $37.97M | -40.0% |
| Q2 FY2017 | Jun 30, 2017 | $16.15M | -71.0% |
| Q1 FY2017 | Mar 31, 2017 | $23.48M | – |
| Q4 FY2016 | Dec 31, 2016 | $59.64M | – |
| Q3 FY2016 | Sep 30, 2016 | $63.30M | – |
| Q2 FY2016 | Jun 30, 2016 | $55.68M | – |
See a number that looks wrong?